Onchocerciasis (river blindness): larva-induced eczema (onchodermatitis) from an important oculocutaneous tropical disease spilling over into North America and Europe.

Onchocerciasis is a leading cause of blindness in the world. It may be seen in temperate climates of the United States and Europe in immigrants and travelers from endemic regions, often linked to poverty and war. One should be aware of an incubation period that can be up to 15 months. In its early stage and throughout its course, onchocerciasis has noteworthy skin findings, facilitating diagnosis, as onchodermatitis resembles common eczema with variable degrees of papular, lichenoid, atrophic, and pigmentary alterations, features not suggestive if one is unaware of an individual's immigration and travel history. The same concept applies for the encysted worms (onchocercomas), as they tend to appear as common skin cysts and benign neoplasms. New methods can be employed to increase diagnostic sensitivity and specificity. Ivermectin is the gold standard of therapy, the use of which has almost miraculously eliminated this disease from large areas of the earth. However, its effect remains isolated to microfilariae and can be devastating in those coinfected with Loa loa. Recently, the symbiotic relationship between adult worms and Wolbachia bacteria has been discovered and, with it, the possibility of adding doxycycline as a treatment option. We also discuss coinfection with HIV and other diseases.

[1]  D. McFarland,et al.  Economic evaluations of onchocerciasis interventions: a systematic review and research needs , 2019, Tropical medicine & international health : TM & IH.

[2]  P. Preux,et al.  Comprehensive management of epilepsy in onchocerciasis-endemic areas: lessons learnt from community-based surveys , 2019, Infectious Diseases of Poverty.

[3]  A. Laudisoit,et al.  High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  T. Geary,et al.  Flubendazole as a macrofilaricide: History and background , 2019, PLoS neglected tropical diseases.

[5]  M. Boussinesq,et al.  Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin , 2018, Infectious Diseases of Poverty.

[6]  R. Idro,et al.  The natural history of nodding syndrome. , 2018, Epileptic disorders : international epilepsy journal with videotape.

[7]  T. Nutman,et al.  A Serological Survey of Human Onchocerciasis in Yemen. , 2018, The American journal of tropical medicine and hygiene.

[8]  M. Vaillant,et al.  Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial , 2018, The Lancet.

[9]  K. Janda,et al.  Noninvasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis , 2018, ACS infectious diseases.

[10]  A. Laudisoit,et al.  High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo , 2018, Infectious Diseases of Poverty.

[11]  J. Keiser,et al.  Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial. , 2018, The Lancet. Infectious diseases.

[12]  B. Boatin,et al.  Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes , 2018, Infectious Diseases of Poverty.

[13]  Solórzano Sánchez,et al.  Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world , 2018, Parasites & Vectors.

[14]  P. Preux,et al.  Report of the first international workshop on onchocerciasis-associated epilepsy , 2018, Infectious Diseases of Poverty.

[15]  D. Boakye,et al.  Onchocerciasis in Yemen: moving forward towards an elimination program. , 2018, International health.

[16]  M. Boussinesq,et al.  Alternative treatment strategies to accelerate the elimination of onchocerciasis , 2018, International health.

[17]  A. Hoerauf,et al.  Validation of onchocerciasis biomarker N-acetyltyramine-O-glucuronide (NATOG) , 2017, Bioorganic & medicinal chemistry letters.

[18]  S. Antinori,et al.  Is imported onchocerciasis a truly rare entity? Case report and review of the literature. , 2017, Travel medicine and infectious disease.

[19]  C. Hennequin,et al.  Imported filariasis in Europe: A series of 31 cases from Metropolitan France. , 2017, European journal of internal medicine.

[20]  D. Boakye,et al.  Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity , 2016, bioRxiv.

[21]  V. Cama,et al.  Detection of Onchocerca volvulus in Skin Snips by Microscopy and Real-Time Polymerase Chain Reaction: Implications for Monitoring and Evaluation Activities. , 2016, The American journal of tropical medicine and hygiene.

[22]  G. Weil,et al.  Diagnostic Tools for Onchocerciasis Elimination Programs. , 2015, Trends in parasitology.

[23]  W. Campbell History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. , 2012, Current pharmaceutical biotechnology.

[24]  A. Hoerauf,et al.  Onchocerciasis: the Role of Wolbachia Bacterial Endosymbionts in Parasite Biology, Disease Pathogenesis, and Treatment , 2011, Clinical Microbiology Reviews.

[25]  R. Schwartz,et al.  Ivermectin: pharmacology and application in dermatology , 2005, International journal of dermatology.

[26]  R. Schwartz,et al.  Cutaneous onchocercoma , 2004, International journal of dermatology.

[27]  W. Kipp,et al.  Simulium neavei-transmitted onchocerciasis: HIV infection increases severity of onchocercal skin disease in a small sample of patients. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  P. Pisella,et al.  [Human onchocerciasis and "sowda" in the Republic of Yemen]. , 2001, Bulletin de l'Academie nationale de medecine.

[29]  M. Ostrowski,et al.  Filarial infections increase susceptibility to human immunodeficiency virus infection in peripheral blood mononuclear cells in vitro. , 2000, The Journal of infectious diseases.

[30]  T. Nutman,et al.  A rapid-format antibody card test for diagnosis of onchocerciasis. , 2000, The Journal of infectious diseases.

[31]  M. Hagan Onchocercal dermatitis: clinical impact. , 1998, Annals of tropical medicine and parasitology.

[32]  D. Richard-Lenoble,et al.  [Onchodermatitis (sowda) in patients in Yémen. Clinical and histologic course after treatment with ivermectin]. , 1997, Sante.

[33]  M. Boussinesq,et al.  Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection , 1997, The Lancet.

[34]  W. Kipp,et al.  Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. , 1995, The American journal of tropical medicine and hygiene.

[35]  Y. Al‐Qubati The first use of ivermectin for the treatment of onchocerciasis in Yemen. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  M. Murdoch,et al.  A clinical classification and grading system of the cutaneous changes in onchocerciasis , 1993, The British journal of dermatology.

[37]  R. Kapila,et al.  Cutaneous Onchocerciasis , 1987, International journal of dermatology.

[38]  W. Campbell,et al.  Ivermectin: a potent new antiparasitic agent. , 1983, Science.

[39]  M. Kerner,et al.  Anthropophily of Simulium damnosum s.l. and its rôle as a vector of human onchocerciasis in the Yemen Arab Republic. , 1982, Tropenmedizin und Parasitologie.

[40]  A. Fawdry Onchocerciasis in South Arabia. , 1957, Transactions of the Royal Society of Tropical Medicine and Hygiene.